Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.
For use during the induction and maintenance of general anesthesia.
Ajou University Hospital, Suwon, Gyeonggido, Korea, Republic of
Sanglah General Hospital, Denpasar, Bali, Indonesia
TriService General Hospital, Taipei, Taiwan
Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China
Seoul National University Hospital, Seoul, Other, Korea, Republic of
Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
Wolfson medical center, Holon, Israel
Asklepieion Hospital of Voula, Athens, Greece
Univeristy of Thessaly, Larissa, Thessaly, Greece
Department of Anaesthesiology, University Hospital of Basel (USB), Basel, Switzerland
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.